Target intelligence / Profile preview

Dynein axonemal heavy chain 10 (DNAH10)

Target
DNAH10
Molecular classification
Motor protein, ATPase, Microtubule-associated protein, Inner arm dynein heavy chain
01

Overview

Dynein axonemal heavy chain 10 (DNAH10) is a large, microtubule-associated motor protein that forms part of the inner arm dynein complex in motile cilia and flagella. It functions as an ATPase, converting ATP hydrolysis into mechanical work to generate force toward the minus ends of microtubules within cilia, driving the motility necessary for processes such as sperm flagellar movement and mucociliary clearance in the airways. DNAH10 also plays a role in epithelial cell proliferation, migration, and differentiation, particularly in skin, where its expression correlates with inflammation and barrier function. Mutations or altered activity of DNAH10 are implicated in male infertility due to defective sperm motility, in axonemal/ciliary disorders, and, in animal models, in congenital scoliosis and body axis defects. There are currently no drugs that specifically target DNAH10, nor is it considered a therapeutic target or clinical biomarker.

Other names
Dynein axonemal heavy chain 10DNAH10KIAA2017FLJ43808Axonemal beta dynein heavy chain 10Ciliary dynein heavy chain 10SPGF56dynein heavy chain 10, axonemaldynein, axonemal, heavy polypeptide 10
02

Biological functions

Ciliary and flagellar motilityATP hydrolysis and force generationSperm motilityEpithelial cell proliferation and differentiationBarrier function and cell migration
03

Disease associations

Male infertility (e.g., spermatogenic failure, oligospermia)Disorders of ciliary motilityCiliopathies (including left-right asymmetry defects, e.g., heterotaxia in model organisms)Scoliosis and body axis curvature disorders (demonstrated in zebrafish models)Skin inflammation (increased expression in inflammatory lesions, e.g., psoriasis)
04

Safety considerations

Alterations in DNAH10 function can result in defects of ciliary motility, with potential developmental and reproductive consequences.There are no therapeutic interventions specifically targeting this protein, and thus no drug-related safety data.

Beyond the preview

Go deeper on Dynein axonemal heavy chain 10 (DNAH10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynein axonemal heavy chain 10 (DNAH10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call